Core Insights - Soleno Therapeutics, Inc. (NASDAQ:SLNO) is recognized as a strong buy stock by Wall Street, with Wells Fargo analyst Derek Archila reiterating a Buy rating and setting a price target of $123.00 [1] Financial Performance - For the three months ended June 30, 2025, Soleno Therapeutics reported a cash usage of $12.6 million in its operating activities [2] - As of the end of the second quarter, the company had $293.8 million in cash, cash equivalents, and marketable securities [2] - The cash balance at the end of Q2 does not include $230 million raised through an underwritten offering of common stock in July [3] - Product revenue for the quarter reached $32.7 million [3] Company Overview - Soleno Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for rare diseases, particularly neurobehavioral and metabolic disorders [4] - The company's lead candidate is Diazoxide Choline Controlled-Release (DCCR), an oral tablet designed to treat Prader-Willi Syndrome (PWS) [4]

Core Insights - Bragar Eagel & Squire, P.C. is investigating potential claims against Soleno Therapeutics, Inc. regarding possible violations of federal securities laws and unlawful business practices [1][2] Investigation Details - The law firm is reaching out to Soleno stockholders who have suffered losses, encouraging them to discuss their legal rights and options [1][2] - There is no cost or obligation for stockholders to inquire about their rights or the ongoing investigation [2] Company Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California, representing individual and institutional investors in various complex litigations [3] Recent Events - On August 15, 2025, Scorpion Capital published a report labeling Soleno's product, Vykat XR, as overpriced and potentially unsafe for children, leading to a significant drop in Soleno's stock price by $5.73 per share, or 7.41%, closing at $71.63 [5]

Core Insights - Acadia Pharmaceuticals' experimental drug carbetocin failed in Phase 3 testing for treating excessive hunger in patients with Prader-Willi syndrome, leading to a nearly 12% drop in its stock price [2][3][4] - The company has decided to halt further development of carbetocin, as it did not show statistically significant improvement compared to the placebo group [4] - Despite the setback, Acadia is positioned for long-term growth with two approved products expected to generate $1 billion in net sales this year and a pipeline of eight disclosed and multiple undisclosed programs [5][6] Company Performance - Acadia Pharmaceuticals' stock fell to approximately $20.80, marking an 11-week low following the news of the drug failure [3] - RBC Capital Markets analyst Brian Abrahams suggested that the stock's decline presents a buying opportunity, maintaining an outperform rating with a price target of $40 [6] Competitive Landscape - The failure of Acadia's drug has positively impacted Soleno Therapeutics, which is also developing a treatment for Prader-Willi syndrome, resulting in a 13.4% increase in its stock price to $64.49 [3][6] - Soleno Therapeutics has received a Relative Strength Rating upgrade, indicating improving technical performance [7][8]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Soleno Therapeutics, Inc. following a negative report on its product Vykat XR, which led to a significant drop in the company's stock price [1][3]. Group 1: Investigation Details - Pomerantz LLP is representing investors of Soleno Therapeutics, Inc. and is looking into claims of securities fraud or other unlawful practices by the company and its officers [1]. - The investigation was prompted by a report from Scorpion Capital that criticized Soleno's only product, Vykat XR, labeling it as overpriced and potentially unsafe for children [3]. Group 2: Stock Price Impact - Following the release of the Scorpion report on August 15, 2025, Soleno's stock price decreased by $5.73 per share, which is a decline of 7.41%, closing at $71.63 per share on the same day [3]. Group 3: Company Background - Soleno Therapeutics, Inc. is a company that has been under scrutiny due to concerns regarding its product and business practices, which may affect investor confidence and market performance [1][3].

Core Insights - Soleno Therapeutics, Inc. is identified as one of the most oversold healthcare stocks in 2025, primarily due to stock volatility following the launch of its FDA-approved product, VYKAT XR, for treating hyperphagia in Prader-Willi Syndrome [2][4] Company Overview - Soleno Therapeutics, Inc. is a clinical-stage biotech company focused on rare diseases, with VYKAT XR being its lead product [2] - The company is pursuing European approval through the EMA, indicating a strategy for international market expansion [3][5] Market Performance - The stock experienced a significant decline of over 10% in mid-August due to a short-seller report raising safety concerns about VYKAT XR, leading to a securities class action investigation [3] - Despite the decline, VYKAT XR has initiated treatment for 646 patients from 295 prescribers, covering over 100 million U.S. lives [3] - The stock has lost approximately 26% in a month, but technical indicators suggest that selling pressure may be nearing exhaustion [4] Analyst Sentiment - Analysts maintain optimistic buy ratings for Soleno Therapeutics, with average price targets ranging from $110 to $120, reflecting confidence in the company's long-term commercial potential [4]

Group 1 - Soleno Therapeutics (NASDAQ: SLNO) recently received approval for its drug Vykat (diazoxide choline) aimed at treating patients over 4 years old with Prader-Willi syndrome [1] - The article promotes a weekly newsletter that provides insights into stocks in the biotech, pharma, and healthcare sectors, highlighting key trends and catalysts that influence market valuations [1] - The investing group Haggerston BioHealth, led by a biotech consultant with over 5 years of experience, offers detailed reports on more than 1,000 companies, including sales forecasts and financial analyses [1]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Soleno Therapeutics, Inc. following a negative report on its product, Vykat XR, which led to a significant drop in the company's stock price [1][2]. Group 1: Company Overview - Soleno Therapeutics, Inc. is publicly traded on NASDAQ under the ticker SLNO [1]. - The company's only product, Vykat XR, has been criticized as overpriced and potentially unsafe for children according to a report by Scorpion Capital [2]. Group 2: Stock Performance - Following the publication of the Scorpion report on August 15, 2025, Soleno's stock price decreased by $5.73 per share, representing a decline of 7.41%, closing at $71.63 per share on the same day [2]. Group 3: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [3].

Core Viewpoint - Soleno Therapeutics, Inc. (SLNO) has experienced a significant decline of 26% over the past four weeks, but it is now in oversold territory, suggesting a potential for a turnaround as analysts expect better earnings than previously predicted [1] Group 1: Technical Indicators - The Relative Strength Index (RSI) is a key technical indicator used to identify oversold conditions, with a reading below 30 indicating a stock may be oversold [2] - SLNO's current RSI reading is 28.11, indicating that heavy selling may be exhausting itself, which could lead to a price rebound [5] - Stocks oscillate between overbought and oversold conditions, and the RSI helps investors identify potential entry points for a rebound [3] Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts to raise earnings estimates for SLNO, resulting in a 26.1% increase in the consensus EPS estimate over the last 30 days [7] - An upward trend in earnings estimate revisions typically correlates with price appreciation in the near term [7] - SLNO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate trends and EPS surprises, indicating a strong potential for a turnaround [8]

Core Insights - Gibbs Mura is investigating legal claims on behalf of investors of Soleno Therapeutics, Inc. (NASDAQ: SLNO) [1] Company Summary - Soleno Therapeutics, Inc. is currently under investigation for potential legal claims related to its operations and investor relations [1] Industry Context - The investigation highlights ongoing scrutiny within the biotechnology sector, particularly regarding investor protection and corporate governance practices [1]

Core Viewpoint - Soleno Therapeutics, Inc. is currently under investigation for potential fraud, providing an opportunity for investors to join the investigation led by the Schall Law Firm [1] Group 1 - The investigation is focused on allegations of fraud related to Soleno Therapeutics, Inc. [1] - Investors are encouraged to participate in the investigation to seek potential remedies [1]